Literature DB >> 12521650

Amenorrhea associated with contraception-an international study on acceptability.

A F Glasier1, K B Smith, Z M van der Spuy, P C Ho, L Cheng, K Dada, K Wellings, D T Baird.   

Abstract

Surveys undertaken in the 1970s and 1980s suggested that amenorrhea was unacceptable to most women, especially in developing countries. More recent research suggests that increasing numbers of women in the developed world prefer to menstruate less often. In a questionnaire survey of 1001 women attending family-planning clinics and 290 contraceptive providers in China, South Africa, Nigeria and Scotland, only among black women in Africa did the majority like having periods. In all other groups, most women disliked periods, which were "inconvenient" and associated with menstrual problems. Given the choice, the majority of Nigerian women would prefer to bleed monthly. Elsewhere, women would opt to bleed only once every 3 months, or not at all. In all except the Chinese centers, the majority of women would be willing to try a contraceptive which induced amenorrhea. Providers tended to overestimate the importance of regular menstruation to their clients. This is an important observation for scientists and funding agencies involved in developing new methods of contraception.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12521650     DOI: 10.1016/s0010-7824(02)00474-2

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  27 in total

1.  A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use.

Authors:  Bliss Kaneshiro; Alison Edelman; Nichole E Carlson; Mark Nichols; Marci Messerle Forbes; Jeffrey Jensen
Journal:  Contraception       Date:  2011-09-28       Impact factor: 3.375

2.  Menstrual-related attitudes and symptoms among multi-racial Asian adolescent females.

Authors:  Li Ping Wong; Ee Ming Khoo
Journal:  Int J Behav Med       Date:  2010-05-04

3.  Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials.

Authors:  Carolina Sales Vieira; Ian S Fraser; Marlena G Plagianos; Anne E Burke; Carolyn L Westhoff; Jeffrey Jensen; Vivian Brache; Luis Bahamondes; Ruth Merkatz; Regine Sitruk-Ware; Diana L Blithe
Journal:  Contraception       Date:  2019-08-06       Impact factor: 3.375

4.  Relationships between menstrual and menopausal attitudes and associated demographic and health characteristics: the Hilo Women's Health Study.

Authors:  Lynn A Morrison; Lynnette L Sievert; Daniel E Brown; Nichole Rahberg; Angela Reza
Journal:  Women Health       Date:  2010-07

5.  Menstrual symptoms: the importance of social factors in women's experiences.

Authors:  Norma O'Flynn
Journal:  Br J Gen Pract       Date:  2006-12       Impact factor: 5.386

6.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 7.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Characteristics of scheduled bleeding manipulation with combined hormonal contraception in university students.

Authors:  Hannah Lakehomer; Paul F Kaplan; David G Wozniak; Christopher T Minson
Journal:  Contraception       Date:  2013-01-08       Impact factor: 3.375

Review 9.  Combination injectable contraceptives for contraception.

Authors:  Maria F Gallo; David A Grimes; Laureen M Lopez; Kenneth F Schulz; Catherine d'Arcangues
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

10.  Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives.

Authors:  Giuseppe Benagiano; Sabina Carrara; Valentina Filippi
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.